Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).

Authors

Luis G. Paz-Ares

Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and CNIO, Madrid, Spain

Luis G. Paz-Ares , Suresh Senan , David Planchard , Luhua Wang , Alicia Cheong , Marie Huong Nguyen , Ruta Slepetis , Everett E. Vokes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.

First Author: Salma K. Jabbour

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

First Author: John M. Varlotto

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505).

First Author: David E. Gerber

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).

First Author: Mustafa Özgüroğlu